Literature DB >> 24353007

Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation.

Ivan Fernandez-Vega1, Jennifer Quirk, Fiona L Norwood, Naomi A Sibtain, Ross Laxton, Istvan Bodi.   

Abstract

Gliomatosis cerebri (GC) is a rare neoplasm in which there is a diffuse cerebral infiltration by malignant glial cells with relative conservation of the underlying structures. A 67-year-old lady was admitted complaining of balance problems, troubled breathing, stuttered speech, decreased mobility, progressive ataxia and also some mild cognitive problems. MRI demonstrated ill defined T2 hyperintensity with mild mass effect mainly involving the brain stem and cerebellar hemispheres, with minor signal abnormalities extending supratentorially along the corticospinal tracts. The imaging appearances were static over a year. No biopsy was performed. The patient received palliative care and died 2 years after initial presentation. Macroscopic examination of the brain showed an extensive firm white-grey lesion predominantly in the cerebellar white matter, the brainstem, spreading to the full length of the spinal cord and invading the sensory ganglia. Histology revealed an extensively infiltrating diffuse glioma with small elongated fusiform nuclei. Diagnosis of GC type 1 was made. Molecular genetic tests revealed BRAF V600E mutation, while no IDH1 & IDH2 mutations were found. GC should be taken into account in the differential diagnoses mainly when there is rapid clinical deterioration without clear evidence of radiological progression. Extensive spinal cord infiltration has been reported only in 9% and BRAF V600E mutation was detected only in one case in GC previously. Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24353007     DOI: 10.1007/s12253-013-9732-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.

Authors:  Sophie Taillibert; Catherine Chodkiewicz; Florence Laigle-Donadey; Massimo Napolitano; Stéphanie Cartalat-Carel; Marc Sanson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri.

Authors:  Mi Jung Kwon; Sung Tae Kim; Mi Jeong Kwon; Doo-Sik Kong; Dageun Lee; Sanghui Park; So Young Kang; Ji-Young Song; Do-Hyun Nam; Yukinari Kato; Yoon-La Choi; Yeon-Lim Suh
Journal:  Brain Pathol       Date:  2011-11-14       Impact factor: 6.508

3.  IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri.

Authors:  Deepti Narasimhaiah; Catherine Miquel; Elisabeth Verhamme; Paul Desclée; Guy Cosnard; Catherine Godfraind
Journal:  Neuropathology       Date:  2011-04-11       Impact factor: 1.906

4.  Targeted therapy for BRAFV600E malignant astrocytoma.

Authors:  Theodore P Nicolaides; Huifang Li; David A Solomon; Sujatmi Hariono; Rintaro Hashizume; Krister Barkovich; Suzanne J Baker; Barbara S Paugh; Chris Jones; Tim Forshew; Guy F Hindley; J Graeme Hodgson; Jung-Sik Kim; David H Rowitch; William A Weiss; Todd A Waldman; C David James
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

5.  Alterations of cell cycle regulators in gliomatosis cerebri.

Authors:  Christian Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Deimling; Gisela Stoltenburg-Didinge; Antje Bornemann; Bernd Romeike; Bernd Sellhaus; Knut Dietzmann
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

6.  Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.

Authors:  Marcel Seiz; Jochen Tuettenberg; Jochen Meyer; Marco Essig; Kirsten Schmieder; Christian Mawrin; Andreas von Deimling; Christian Hartmann
Journal:  Acta Neuropathol       Date:  2010-06-01       Impact factor: 17.088

7.  Impact of adjuvant chemotherapy for gliomatosis cerebri.

Authors:  Doo-Sik Kong; Sung Tae Kim; Jung-Il Lee; Yeon-Lim Suh; Do Hoon Lim; Won Seog Kim; Ki-Hoon Kwon; Kwan Park; Jong Hyun Kim; Do-Hyun Nam
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

8.  Gliomatosis cerebri, report of a clinically diagnosed and histologically confirmed case.

Authors:  D Troost; H Kuiper; J Valk; P Fleury
Journal:  Clin Neurol Neurosurg       Date:  1987       Impact factor: 1.876

9.  Gliomatosis cerebri: clinical features, treatment, and prognosis.

Authors:  D G Kim; H J Yang; I A Park; J G Chi; H W Jung; D H Han; K S Choi; B K Cho
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

Review 10.  Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease.

Authors:  Cort D Lawton; Daniel T Nagasawa; Isaac Yang; Richard G Fessler; Zachary A Smith
Journal:  J Neurosurg Spine       Date:  2012-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.